Karuna Therapeutics surges 47% after Bristol Myers Squibb announces $14 billion deal
Bristol Myers Squibb said it agreed to buy biopharmaceutical company Karuna Therapeutics for $14 billion in cash.
Source link
- Israel’s AI-powered ‘mass assassination factory’
- Here’s when you can visit a national park for free in 2024
